To participate in a clinical trial Register now
To participate in a clinical trial Register now
If you believe that one of the studies below is appropriate for you, please speak to your treating physician and obtain a medical referral letter including all relevant treatment and diagnostic information.
To facilitate prompt review of referral, please include the following:
The team here at Scientia Clinical Research would love to welcome you on a clinical trial. To get started you will need a medical referral letter including all relevant treatment and diagnostic information. You may also speak to your oncology consultant, and they will be able to contact us if you are a suitable candidate for referral.
To facilitate prompt review of referral, please include the following:
If you have have any questions please email our team at : ContactUs@scientiaclinicalresearch.com.au
Randwick, Sydney
Advanced Solid Tumours
Randwick, Sydney
Haematological cancers for 955
Randwick, Sydney
Advanced/Metastatic Colorectal Cancer
Randwick, Sydney
Advanced Solid Tumours
Randwick, Sydney
Advanced Solid Tumours
Randwick, Sydney
Advanced solid tumours
Randwick, Sydney
Advanced cancer, Advanced solid tumours
Randwick, Sydney
Advanced solid tumours, gastrointestinal tumours of are interest
Randwick, Sydney
Locally Advanced or Metastatic HER2-Expressing Cancers
Randwick, Sydney
Advanced or Metastatic Solid Tumors Harboring RAS Mutations and Enriched for CEACAM5 Expression
Randwick, Sydney
Advanced Solid Tumours
Randwick, Sydney
Adult participants and with solid tumors as monotherapy
Randwick, Sydney
Advanced Solid Tumours
Randwick, Sydney
Advanced Solid Tumours
Randwick, Sydney
Advanced Solid Tumours
Randwick, Sydney
Advanced Solid Tumours
Randwick, Sydney
Participants with MTAP-deleted solid tumors
Randwick, Sydney
Advanced Solid Tumours
Randwick, Sydney
Advanced Solid Tumours
Randwick, Sydney
Advanced Solid Tumours and Lymphomas
Randwick, Sydney
Advanced Solid Tumours
Randwick, Sydney
Advanced Metastatic Solid Tumors
Randwick, Sydney
Advanced Solid Tumours
Randwick, Sydney
Advanced Solid Tumours
Randwick, Sydney
Advanced/Metastatic Gastrointestinal Tumors
Randwick, Sydney
Advanced/Metastatic Solid Tumors
Randwick, Sydney
Advanced Solid Tumours
Randwick, Sydney
Advanced solid tumours
Randwick, Sydney
Friedreich’s Ataxia
Randwick, Sydney
Adult participants and with solid tumors as monotherapy
Randwick, Sydney
Adult participants and with solid tumors as monotherapy
Randwick, Sydney
Glioblastoma
Randwick, Sydney
Relapsed/Refractory B-cell Non-Hodgkin Lymphoid Malignancies (NHLs)
Randwick, Sydney
Advanced Solid Tumours
Randwick, Sydney
Advanced or Metastatic Solid Tumors
Randwick, Sydney
Advanced Solid Tumors
Randwick, Sydney
Advanced or Metastatic Solid Tumours
Randwick, Sydney
Advanced Solid Tumors
Randwick, Sydney
Basal Cell Carcinomas
Randwick, Sydney
Advanced solid tumors.
Randwick, Sydney
Advanced Solid Tumours
Randwick, Sydney
Advanced Solid Tumors
Randwick, Sydney
Advanced Metastatic Solid Tumours
Randwick, Sydney
Adult participants and with solid tumors as monotherapy
Randwick, Sydney
Advanced Solid Tumours
A Phase 1, First-in-human Study of JNJ-80948543, a T-cell Redirecting Antibody, in Participants with NHL and CLL
Randwick, Sydney
Advanced Solid Tumours
First-in-Human, Phase 1 Study of AMT-676, an Anti-CDH17 Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors
Randwick, Sydney
Advanced solid tumours, gastrointestinal tumours of are interest
A Phase 1, Multicenter, Open-Label, First-in-Human Study of the Safety and Pharmacokinetics of AMX-818 Alone and in Combination with Pembrolizumab in Participants with Locally Advanced or Metastatic HER2-Expressing Cancers
Randwick, Sydney
Locally Advanced or Metastatic HER2-Expressing Cancers
Randwick, Sydney
Advanced Solid Tumours and Mature B-cell NHL
A Phase 1a/1b, first-in-human, open-label, non-randomized, multicenter, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AXA-042 as monotherapy and in combination with checkpoint inhibitors in subjects with advanced solid tumors.
Randwick, Sydney
Advanced Solid Tumours
A Phase I, International, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of BL0020 as A Single Agent in Patients with Advanced Solid Tumors
Randwick, Sydney
Advanced Solid Tumours
A Phase 1/2, Multicenter, Open-label Study of IBI130 in Subjects with Unresectable, Locally Advanced or Metastatic Solid Tumors
Randwick, Sydney
Metastatic Solid Tumours
A Phase Ⅰ/Ⅱ, Multicenter, Open-label Study of IBI3004 in Subjects with Unresectable, Locally Advanced or Metastatic Solid Tumors
Randwick, Sydney
Advanced solid tumours, gastrointestinal tumours of are interest
A Multicentre,Study of IBI133 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumours
Randwick, Sydney
Advanced Metastatic Solid Tumors
A Phase 1, open-label, multicenter clinical trial of S095035 (MAT2A inhibitor) in adult participants with advanced or metastatic solid tumors with homozygous deletion of MTAP
Randwick, Sydney
Participants with MTAP-deleted solid tumors
A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study of MVC-101, An EGFR x CD3 COnditional Bispecific Redirected Activation (COBRA) Protein in Patients with Unresectable Locally Advanced or Metastatic Cancer
Randwick, Sydney
Unresectable Locally Advanced or Metastatic Cancer, Non-small Cell Lung Cancer, Head and Neck Squamous cell carcinoma
A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS5001, an Anti-ROR1 Antibody Drug Conjugate, in Patients with Advanced Solid Tumors and Lymphomas
Randwick, Sydney
Advanced Solid Tumours and Lymphomas
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1303 in Patients with Advanced/Metastatic Solid Tumors
Randwick, Sydney
Advanced Metastatic Solid Tumors
A Phase 1/2a, multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1311 in Subjects with Advanced/Metastatic Solid Tumours.
Randwick, Sydney
Advanced Solid Tumours
A Phase 1, Multicenter, Open-label, Dose Escalation, and Dose Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumour Activity of DCSZ11 as a Monotherapy in Patients with Advanced or metastatic Solid Tumours
Randwick, Sydney
Advanced Solid Tumours
A first-in-human, Phase 1/2, open-label, multi-center, dose-escalation, dose-optimization, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of PARP1 selective inhibitor, IMP1734, in patients with advanced solid tumors
Randwick, Sydney
Adult participants and with solid tumors as monotherapy
An Open-Label, Multicenter, First-in-Human, Phase 1 Study of ES009 in Subjects with Locally Advanced or Metastatic Solid Tumors
Randwick, Sydney
Metastatic Solid Tumours
A Phase 1 / 2 First-in-human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01- Positive Participants with Advanced PRAME-Positive Cancers
Randwick, Sydney
Advanced Positive Cancers
A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer
Randwick, Sydney
Relapsed/Refractory B-cell Non-Hodgkin Lymphoid Malignancies (NHLs)
Phase I/II Study to Assess the Safety, tolerability, Pharmacokinetics and efficacy of JSKN033 in Patients with Advanced or Metastatic Solid Malignant Tumors
Randwick, Sydney
HER2-expressing Advanced or Metastatic Solid Tumours
A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination with an Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors. “ABILITY Study”
Randwick, Sydney
Advanced Solid Tumours
A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmcodynamics and Preliminary Efficacy of MT-302 in Adults with Advanced or Metastatic Epithelial Tumors.
Randwick, Sydney
Advanced Solid Tumours
A Phase 1, open label single-arm two-part study to investigate safety,
pharmacokinetics, and preliminary efficacy of pan-RAF/MEK glue NST-628
oral tablets in subjects with solid tumors harboring genetic alterations in the
MAPK pathway and with other solid tumors
Randwick, Sydney
Solid tumors harboring genetic alterations in the MAPK pathway and with other solid tumors
A Phase I/II, Open-label, Multicentre, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics and Anti-tumor Activity of SCTB14 in Patients With Advanced Malignant Solid Tumours
Randwick, Sydney
Adult Patients With Advanced Malignant Solid Tumours
AN OPEN-LABEL, SINGLE-ARM, MULTI-CENTER PHASE I/IIA CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS EXPRESSING CLAUDIN 18.2
Randwick, Sydney
Advanced Solid Tumours
This is an open-label, dose-escalation, multi-center phase 1 study evaluating the safety, tolerability, and pharmacokinetics (PK) of SR-8541A, an ENPP1 inhibitor
Randwick, Sydney
Advanced Metastatic Solid Tumours
A multi-center, open-label Phase 1 trial of SNV1521 administered orally as a single agent, to evaluate the safety, tolerability, preliminary anti-tumor activity and determine the maximum
tolerated dose (MTD) and RDE(s) of monotherapy SNV1521 in adult participants with advanced solid tumors
Randwick, Sydney
Adult participants and with solid tumors as monotherapy
Register interest in a clinical trial
"*" indicates required fields
Register interest in a clinical trial
"*" indicates required fields
We respect your privacy. By submitting your details you are agreeing to our privacy policy. You can unsubscribe at any time.